{"filing":{"accession_number":"0001193125-26-337270","cik":"0001612042","ticker":"ASND","company_name":"Ascendis Pharma A/S","form":"6-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"d169607d6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1612042/000119312526337270/d169607d6k.htm"},"events":[{"id":24537,"run_id":22244,"accession_number":"0001193125-26-337270","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The 6-K discloses material clinical trial updates for Ascendis's achondroplasia programs, including Week 78 COACH combination therapy results showing sustained efficacy at the 97th percentile growth velocity, Week 104 ApproaCH monotherapy data, and YUVIWEL U.S. launch progress (170+ patient enrollments, 65%+ reimbursement approval). These are significant operational and clinical development milestones that would affect investor assessment of the company's pipeline and commercialization trajectory, though they do not fit neatly into discrete event categories like earnings_release or ma_activity.","company_name":"Ascendis Pharma A/S","ticker":"ASND","filing_date":"2026-08-06","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":25131,"accession_number":"0001193125-26-337270","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The 6-K discloses material clinical trial updates for Ascendis's achondroplasia programs, including Week 78 COACH combination therapy results showing sustained efficacy at the 97th percentile growth velocity, Week 104 ApproaCH monotherapy data, and YUVIWEL U.S. launch progress (170+ patient enrollments, 65%+ reimbursement approval). These are significant operational and clinical development milestones that would affect investor assessment of the company's pipeline and commercialization trajectory, though they do not fit neatly into discrete event categories like earnings_release or ma_activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:06:50.077899+00:00","company_name":"Ascendis Pharma A/S","ticker":"ASND","filing_date":"2026-08-06"}]}